Your session is about to expire
← Back to Search
NK Cell Therapy
aNK (NK-92) for Merkel Cell Carcinoma
Phase 2
Waitlist Available
Research Sponsored by ImmunityBio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
Study Summary
Phase II study to determine the effects of aNK infusions in combination with ALT-803 in patients with stage III (IIIB) or stage (IV) merkel cell carcinoma (MCC).
Eligible Conditions
- Merkel Cell Carcinoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Progression Free Survival
Secondary outcome measures
Overall Response Rate
Overall survival
Quality of life assessment
+2 moreOther outcome measures
Exploratory Genomic, Transcriptomic, and Proteomic Analysis
Trial Design
1Treatment groups
Experimental Treatment
Group I: aNK (NK-92)Experimental Treatment1 Intervention
aNK (activated NK-92, formerly Neukoplast)
Find a Location
Who is running the clinical trial?
ImmunityBio, Inc.Lead Sponsor
63 Previous Clinical Trials
5,112 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger